Перейти к контенту
Main image
Печать
MONOCLONAL ANTI-TRANCE, CLONE: 70525
Кат. №: T2942
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Печать
MONOCLONAL ANTI-TRANCE, CLONE: 70525
Main image
Кат. №: T2942
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Main image
Печать
MONOCLONAL ANTI-TRANCE, CLONE: 70525
Кат. №: T2942
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Description_x000D_ General description_x000D_ TRANCE (TNF-related activation-induced cytokine), also called RANKL (RANK ligand), OPGL (Osteoprotegrin ligand), and ODF (Osteoclast differentiation factor) is a member of tumor necrosis factor superfamily that is expressed on the surface of osteoblasts and is released by activated T cells. When TRANCE binds to its receptor RANK it stimulates the formation, activation, survival and adherence of osteoclasts that increases the bone resorption. These effects are inhibited when RANKL binds to OPG that leads to decrease in bone resorption process and increase in bone volume and density. The TRANCE (RANKL)/RANK/OPG collectively activates NF-κB, JNK, Akt, p38, ERK, NFATc1 pathways. This axis is vital for maintaining the bone density, dendritic cell survival, B cell differentiation, mammary gland development. This signaling pathway maintains the osteoclast biology and is a therapeutic target for osteoporosis. Monoclonal Anti-TRANCE antibody recognizes human TRANCE (~27 kDa). This antibody demonstrates 5% cross reactivity with recombinant mouse TRANCE._x000D_ Specificity_x000D_ The antibody show <5% cross-reactivity with recombinant mouse TRANCE._x000D_ Immunogen_x000D_ recombinant human TRANCE_x000D_ Application_x000D_ Anti-TRANCE antibody may be used for immunohistochemistry of paraffin-embedded tissue sections at a working concentration of 8-25 μg/ml. For ELISA a concentration of 0.5-1.0 μg/ml is recommended. The antibody is also suitable for neutralization reactions (ND50 is 0.02-0.06 μg/ml)._x000D_ Physical form_x000D_ Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline with 5% trehalose._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Related Categories
Alphabetical Index, Antibodies, Antibodies for Apoptosis, Antibodies for Cell Biology, Antibodies to Cytokines and Growth Factors, Antibodies to Death Receptor Ligands, Antibodies to Tumor Necrosis Factor (TNF) Superfamily, Cell Biology, Cell Signaling and Neuroscience, Cytokines and Growth Factors, Cytokines, Growth Factors and Hormones, Primary Antibodies, RANK, Osteoprotegerin and TRAIL, TR-TR, Tumor Necrosis Factor (TNF) SuperfamilyMore... conjugate
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.
Description_x000D_ General description_x000D_ TRANCE (TNF-related activation-induced cytokine), also called RANKL (RANK ligand), OPGL (Osteoprotegrin ligand), and ODF (Osteoclast differentiation factor) is a member of tumor necrosis factor superfamily that is expressed on the surface of osteoblasts and is released by activated T cells. When TRANCE binds to its receptor RANK it stimulates the formation, activation, survival and adherence of osteoclasts that increases the bone resorption. These effects are inhibited when RANKL binds to OPG that leads to decrease in bone resorption process and increase in bone volume and density. The TRANCE (RANKL)/RANK/OPG collectively activates NF-κB, JNK, Akt, p38, ERK, NFATc1 pathways. This axis is vital for maintaining the bone density, dendritic cell survival, B cell differentiation, mammary gland development. This signaling pathway maintains the osteoclast biology and is a therapeutic target for osteoporosis. Monoclonal Anti-TRANCE antibody recognizes human TRANCE (~27 kDa). This antibody demonstrates 5% cross reactivity with recombinant mouse TRANCE._x000D_ Specificity_x000D_ The antibody show <5% cross-reactivity with recombinant mouse TRANCE._x000D_ Immunogen_x000D_ recombinant human TRANCE_x000D_ Application_x000D_ Anti-TRANCE antibody may be used for immunohistochemistry of paraffin-embedded tissue sections at a working concentration of 8-25 μg/ml. For ELISA a concentration of 0.5-1.0 μg/ml is recommended. The antibody is also suitable for neutralization reactions (ND50 is 0.02-0.06 μg/ml)._x000D_ Physical form_x000D_ Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline with 5% trehalose._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Related Categories
Alphabetical Index, Antibodies, Antibodies for Apoptosis, Antibodies for Cell Biology, Antibodies to Cytokines and Growth Factors, Antibodies to Death Receptor Ligands, Antibodies to Tumor Necrosis Factor (TNF) Superfamily, Cell Biology, Cell Signaling and Neuroscience, Cytokines and Growth Factors, Cytokines, Growth Factors and Hormones, Primary Antibodies, RANK, Osteoprotegerin and TRAIL, TR-TR, Tumor Necrosis Factor (TNF) SuperfamilyMore... conjugate
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.